SUPPRELIN Drug Patent Profile
✉ Email this page to a colleague
When do Supprelin patents expire, and what generic alternatives are available?
Supprelin is a drug marketed by Shire and Endo Operations and is included in two NDAs. There is one patent protecting this drug.
The generic ingredient in SUPPRELIN is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Supprelin
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SUPPRELIN?
- What are the global sales for SUPPRELIN?
- What is Average Wholesale Price for SUPPRELIN?
Summary for SUPPRELIN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 35 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,740 |
| Drug Prices: | Drug price information for SUPPRELIN |
| What excipients (inactive ingredients) are in SUPPRELIN? | SUPPRELIN excipients list |
| DailyMed Link: | SUPPRELIN at DailyMed |
Recent Clinical Trials for SUPPRELIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 3 |
| Southwest Oncology Group | Phase 3 |
| University of Colorado, Denver | Phase 2 |
US Patents and Regulatory Information for SUPPRELIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-001 | Dec 24, 1991 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Endo Operations | SUPPRELIN LA | histrelin acetate | IMPLANT;SUBCUTANEOUS | 022058-001 | May 3, 2007 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-002 | Dec 24, 1991 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-003 | Dec 24, 1991 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SUPPRELIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-001 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-003 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-002 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SUPPRELIN
See the table below for patents covering SUPPRELIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ireland | 49822 | WATER-SOLUBLE PEPTIDES AFFECTING GONADAL FUNCTION | ⤷ Sign Up |
| South Africa | 8003112 | ⤷ Sign Up | |
| Canada | 1154758 | PEPTIDES HYDROSOLUBLES AYANT UNE ACTION SUR LES GONADES (WATER-SOLUBLE PEPTIDES AFFECTING GONADAL FUNCTION) | ⤷ Sign Up |
| Philippines | 15362 | WATER SOLUBLE PEPTIDES AFFECTING GONADAL FUNCTION | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
